BAY-43-9006 Bayer/Onyx.
Bayer and Onyx are developing BAY-43-9006, an oral cytostatic Raf kinase inhibitor for the potential treatment of colorectal and breast cancers, hepatocellular carcinoma and non-small-cell lung cancer, in addition to acute myelogenous leukemia, myelodysplastic syndrome and other cancers. A US IND was filed in May 2000 and by February 2003 BAY-43-9006 was in phase II trials, with phase III trials expected to begin later in 2003.
Lee
John T
JT
Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, East Fifth Street, Greenville, NC 27858-4553, USA.
McCubrey
James A
JA
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D000077157:Sorafenib; D013678:Technology, Pharmaceutical / Q000379:methods*
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D015507:Drugs, Investigational; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib